Quest Genomics

Nanjing Quest Genomics Co., Ltd. specializes in the research, development, and production of instruments and reagents for tumor gene detection, with a particular emphasis on tumor liquid biopsy. Founded in 2012 and headquartered in Nanjing, China, the company is dedicated to advancing genetic testing technologies, particularly in the areas of digital PCR and next-generation sequencing (NGS). Quest Genomics has developed a range of products for detecting mutations in key genes, including HER2, PIK3CA, EGFR, and KRAS, aimed at facilitating targeted therapy and monitoring minimal residual disease (MRD) in cancer patients. Their solutions support the early diagnosis of tumor recurrence, metastasis, and disease progression, thereby enhancing treatment outcomes. Additionally, the company maintains a technology development and overseas market center in San Diego, California, to bolster its global reach and innovation capabilities.